MAR 12 2008 TO

Substitute for form 144B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/561,449			
Filing Date	December 20, 2005			
First Named Inventor	Luc Bouwens et al.			
Art Unit	1647			
Examiner Name	Daniel C. Gamett			

Sheet		1	of	3	Attorney Docket Number	BOUW3001/JEK	
			NON	PATENT LITERAT	TURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T <sub>2</sub>
		European Search Report dated November 16, 2007 relating to European Application EP 04 73 7673					
		RAMIYA K. VIJAYAKUMAKUMAR ET AL., "Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells", Nature Medicine, Nature America, Vol. 6, No. 3, March 2000 (2000-03) pages 278-282, XP000864764					
		HIROSATO MASHIMA ET AL., "Betacellulin and Activin A Coordinately Convert Amylase-secreting Pancreatic AR42J Cells into insulin-secreting Cells", <u>Journal of Clinical Investigation</u> , Vol. 97, No. 7, April 1 1996 (1996-04-01), pages 1647-1657, XP000670303					
		KI-HO SONG ET AL., "In vitro transdifferentiation of adult pancreatic acinar cells into insulin- expressing cells", <u>Biochemical and Biophysical Research Communications</u> , Vol. 316, No. 4, April 16, 2004 (2004-04-16), pages 1094-1100, XP004496901					
		an Experime	ental Mod	el of Diabetes", End	Pancreatic ß Cells from Intra- ocrinology, Vol. 142, No. 11, v.endo.endojournals.org)		
					increatic acinoductal transdiff g, Springer-Velag 2000, Vol. 4		
					of Gastrin and Expression of interology, Vol. 123, 2001, pa		
			differentia	ited but Not From No	tes ß Cell Neogenesis and Indormal Exocrine Pancreas Tiss		
					ne Intermediate Cells in Strep <u>ol</u> , Vol. 15, No. 3, 1997, pages		
				 AL., "Pluripotency of . 418, July 2002, pag	mesenchymal stem cells der ges 41-49	rived from adult	

Examiner Signature	I .	Date Considered	-

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Complete if Known Substitute for form 144B/PTO Application Number 10/561,449 Filing Date December 20, 2005 INFORMATION DISCLOSURE First Named Inventor Luc Bouwens et al. STATEMENT BY APPLICANT Art Unit 1647 (Use as many sheets as necessary) Examiner Name Daniel C. Gamett Sheet of Attorney Docket Number BOUW3001/JEK NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title T2 Initials\* of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), No.1 volume-issue number(s), publisher, city and/or country where published. CORENTIN CRAS-MÉNEUR ET AL., "Epidermal Growth Factor Increases Undifferentiated Pancreatic Embryonic Cells In Vitro: A Balance Between Proliferation and Differentiation". Diabetes, Vol. 50, July 2001, pages 1571-1579 PÄIVI J. MIETTINAN ET AL., "Impaired migration and delayed differentiation of pancreatic islet cells in mice lacking EGF-receptors", Development, Vol. 127, 2000, pages 2617-2627 KOJI YAMAMOTO ET AL., "Recombinant Human Betacellulin Promotes the Neogenesis of ß-Cells and Ameliorates Glucose Intolerance in Mice With Diabetes Induced by Selective Alloxan Perfusion", Diabetes, Vol. 40, December 2000, pages 2021-2027 EUGENIO BERTELLI ET AL., "Intermediate endocrine-acinar pancreatic cells in duct ligation conditions", American Physiological Society, Vol. 273, 1997, pages 1641-1649 SUSAN BONNER-WEIR ET AL., "In vitro cultivation of human islets from expanded ductal tissue, PNAS, Vol. 97, No. 14, July 5, 2000, pages 7999-8004 LUC BOWENS, "Transdifferentiation Versus Stem Cell Hypothesis for the Regeneration of Islet Beta-Cells in the Pancreas", Microscopy Research And Technique, Vol. 43, 1998, pages LUC BOWENS ET AL., "Islet cell neogenesis in the pancreas", Biomedische-Bibl, 1996, Vol. 427, pages 553-560 STEPHEN J. BRAND ET AL., "Pharmacological Treatment of Chronic diabetes by Stimulating Pancreatic β-Cell Regeneration with Systemic Co-administration of EGF and Gastrin", Pharmaeology & Toxicology, Vol. 91, 2000, pages 414-420 JEAN BUTEAU ET AL., "Glucagon-Like Peptide 1 Induces Pancreatic β-Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor", Diabetes, Vol. 52, January 2003, pages 124-132

Examiner	Date	1
Signature	Considered	1

DANIEL C. DRUCKER, "Glucagon-Like Peptides: Regulators of Cell Proliferation,

Differentiation, and Apoptosis", Molecular Endocrinology, Vol. 17, No. 2, 2003, pages 151-171

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 144B/PTO			Complete if Known					
			Application Number	10	10/561,449			
INFORMATION DISCLOSURE			Filing Date	D	December 20, 2005			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Invento	or Li	Luc Bouwens et al.		
<u>ا</u>		S many sheets as			Art Unit	10	1647	
(Use as many sneets as necessary)				Examiner Name	D	Daniel C. Gamett		
Sheet	Sheet 3 of 3			3	Attorney Docket Nu	mber B	BOUW3001/JEK	
			NON	PATENT LITERAT	TURE DOCUMENTS			
Examiner Initials*	Cite No.1	of the item (bo	ok, ma	igazine, journal, seria	ETTERS), title of the al, symposium, catalondor country where p	g, etc.), da		T <sub>2</sub>
					enesis - Development 3, July 2002, pages 52		sms and	
-								
	ļ.,							
		-						
Examiner						Date	4	

attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached